CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 81 enrolled
Drug / intervention
yttrium Y 90 microspheres (TheraSphere®)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00493883
NCT00493883Phase 2Completed
CompareCT.gov

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

Southwestern Regional Medical Center·interventional·Posted Jun 28, 2007·Updated May 13, 2015

In Brief

A Phase 2 clinical trial evaluating yttrium Y 90 microspheres (TheraSphere®) for Carcinoma, Hepatocellular and Liver Neoplasms. Completed, enrolled 81 participants across 1 site.

Detailed Summary

The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity. The study has the following objectives: * Provide supervised access to treatment with TheraSphere to eligible patients with primary and metastatic cancer to the liver. * Evaluate patient experience and toxicities associated with TheraSphere treatment * Evaluate predisposing factors that may influence results and toxicity

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular, Liver Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 28, 2007
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 19.0 years ago

Interventions

yttrium Y 90 microspheres (TheraSphere®)device

Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver